{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:39Z","timestamp":1786119339121,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1097\/mnm.0b013e328335a5ed","type":"journal-article","created":{"date-parts":[[2010,1,30]],"date-time":"2010-01-30T02:27:16Z","timestamp":1264818436000},"page":"249-253","source":"Crossref","is-referenced-by-count":23,"title":["Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases"],"prefix":"10.1097","volume":"31","author":[{"given":"Athanasios G.","family":"Zafeirakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios A.","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios S.","family":"Limouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210212","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0090-4295(83)90147-4","article-title":"Spread of prostatic cancer to bone","volume":"21","author":"Jacobs","year":"1983","journal-title":"Urology"},{"key":"R2-11-20210212","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R3-11-20210212","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1210\/jc.2003-030910","article-title":"Markers of bone remodeling in metastatic bone disease","volume":"88","author":"Fohr","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-11-20210212","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0305-7372(96)90021-3","article-title":"Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment","volume":"22","author":"Vinholes","year":"1996","journal-title":"Cancer Treat Rev"},{"key":"R5-11-20210212","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.juro.2007.05.029","article-title":"Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach","volume":"178","author":"Koopmans","year":"2007","journal-title":"J Urol"},{"key":"R6-11-20210212","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/cncr.10522","article-title":"The clinical use of bone resorption markers in patients with malignant bone disease","volume":"94","author":"Coleman","year":"2002","journal-title":"Cancer"},{"key":"R7-11-20210212","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1158\/1078-0432.CCR-03-0735","article-title":"Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer","volume":"10","author":"Michaelson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R8-11-20210212","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1097\/01.blo0000092979.12414.54","article-title":"Biochemical markers and skeletal metastases","volume":"415","author":"Demers","year":"2003","journal-title":"Clin Orthop"},{"key":"R9-11-20210212","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1365-2265.2007.03112.x","article-title":"The use of molecular markers of bone turnover in the management of patients with metastatic bone disease","volume":"68","author":"Seibel","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R10-11-20210212","first-page":"1765","article-title":"A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index","volume":"4","author":"Imbriaco","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R11-11-20210212","first-page":"242","article-title":"Serum concentrations of IL-2 and TNF-a in patients with painful bone metastases: correlation with responses to 89SrCl2 therapy","volume":"47","author":"Fang","year":"2006","journal-title":"J Nucl Med"},{"key":"R12-11-20210212","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","article-title":"The use of nitrogen mustards in the palliative treatment of cancer","volume":"1","author":"Karnofsky","year":"1948","journal-title":"Cancer"},{"key":"R13-11-20210212","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(00)02144-9","article-title":"Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity","volume":"355","author":"Hoskin","year":"2000","journal-title":"Lancet"},{"key":"R14-11-20210212","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"R15-11-20210212","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pros.2990200302","article-title":"Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?","volume":"20","author":"Arai","year":"1992","journal-title":"Prostate"},{"key":"R16-11-20210212","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0009-9120(95)02001-2","article-title":"New and traditional serum markers of bone metabolism in the detection of skeletal metastases","volume":"29","author":"Plebani","year":"1996","journal-title":"Clin Biochem"},{"key":"R17-11-20210212","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s002590050430","article-title":"Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients","volume":"26","author":"Lorente","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"R18-11-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2385-4-3","article-title":"Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy","volume":"4","author":"Schoenberger","year":"2004","journal-title":"BMC Nucl Med"},{"key":"R19-11-20210212","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1464-410X.2006.06604.x","article-title":"Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer","volume":"99","author":"Hegele","year":"2007","journal-title":"BJU Int"},{"key":"R20-11-20210212","first-page":"2653","article-title":"Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase","volume":"19","author":"Wolff","year":"1999","journal-title":"Anticancer Res"},{"key":"R21-11-20210212","first-page":"125","article-title":"Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases","volume":"12","author":"Francini","year":"1993","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R22-11-20210212","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1464-410x.2001.00105.x","article-title":"The serum level of the aminoterminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone","volume":"87","author":"Koizumi","year":"2001","journal-title":"BJU Int"},{"key":"R23-11-20210212","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen Type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"key":"R24-11-20210212","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/pros.20917","article-title":"Complications in men with metastatic prostate cancer treated with zoledronic acid","volume":"69","author":"Lein","year":"2009","journal-title":"Prostate"},{"key":"R25-11-20210212","first-page":"41","article-title":"Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption","volume":"13","author":"Percival","year":"1987","journal-title":"Eur J Surg Oncol"},{"key":"R26-11-20210212","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z","article-title":"Biochemical markers and skeletal metastases","volume":"88","author":"Demers","year":"2000","journal-title":"Cancer"},{"key":"R27-11-20210212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1097-0045(19990101)38:1<28::AID-PROS3>3.0.CO;2-M","article-title":"Inability of bone turnover marker as strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade","volume":"38","author":"Akimoto","year":"1999","journal-title":"The Prostate"},{"key":"R28-11-20210212","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/45.8.1240","article-title":"Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases","volume":"45","author":"Berruti","year":"1999","journal-title":"Clin Chem"},{"key":"R29-11-20210212","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1055-9965.EPI-05-0492","article-title":"The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients","volume":"15","author":"Leeming","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R30-11-20210212","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"R31-11-20210212","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"key":"R32-11-20210212","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/clinchem\/47.8.1443","article-title":"Interlaboratory variation of biochemical markers of bone turnover","volume":"47","author":"Seibel","year":"2001","journal-title":"Clin Chem"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0b013e328335a5ed","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:18:58Z","timestamp":1786040338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006231-201003000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e328335a5ed","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}